Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Quoin Pharmaceuticals ( (QNRX) ) has shared an update.
On June 24, 2025, Quoin Pharmaceuticals announced that the U.S. FDA granted Rare Pediatric Disease Designation for its lead asset, QRX003, aimed at treating Netherton Syndrome. This designation could enhance Quoin’s industry positioning by potentially expediting the development and approval process, benefiting stakeholders involved in the treatment of rare diseases.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases.
Average Trading Volume: 291,496
Technical Sentiment Signal: Sell
Current Market Cap: $5.28M
Find detailed analytics on QNRX stock on TipRanks’ Stock Analysis page.